 Xconomy | Celgene antes up $35M, snags buyout option on VentiRx cancer work FierceBiotech The first will be a combination study with docetaxel for ovarian cancer with the second--a combination with rituximab--aimed at head and neck cancer. For VentiRx the deal with Celgene provides R&D support for the proof-of-concept stage. Celgene is ... Celgene Puts $35M into VentiRx, Gets Option to Buy Cancer Drugmaker |
